Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

$7.8 Billion Molecular Diagnostics Market Positioned for Significant Growth

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
New analysis sizes the MDx market, analyzes key market drivers, and provides detailed forecasts through 2015 across major sectors.

G2 Intelligence announces the release of U.S. Molecular Diagnostic and Genomic Testing 2013-2015: Laboratory Industry Analysis, Trends, and Forecasts, a new resource for stakeholders in MDx testing. In conjunction with the release of the study, G2 currently gauges the MDx market at $7.8 billion in 2013.

“Like other health care sectors, molecular diagnostics is experiencing disruptive forces that are redefining the very core of care, delivery, and reimbursement models,” according to L. Eleanor Herriman, M.D. M.B.A., Managing Director of G2 Intelligence Advisory Services, and one of the report’s analysts. “These forces are largely driven by the reactions of health care payers and policy makers to the national health care cost crisis, and the shift to a value-based system. MDx is uniquely positioned to play a central role in value-based health care, but must first navigate some challenging regulatory and payer issues.”

U.S. Molecular Diagnostic and Genomic Testing clarifies the market with:

•    Market sizing and growth forecasts through 2015 across seven MDx sectors:
o    Hematology-Oncology (Hem-Onc)
o    Pharmacogenomics (PGx)
o    Women’s Health
o    General Infectious
o    Inherited
o    Transplant
o    Blood Screening

•    Analysis of key market drivers and inhibitors

•    Platform usage by test type including:

o    Abbott, ABI, Access, Autogenomics, BD (Becton, Dickinson and Company), Bio Rad Biocare, Cepheid, Dako, Focus, GenMark, Gen-Probe, Leica, Luminex Qiagen, Roche, Ventana and more

•    Menu availability and in-house vs. send out analysis, by test including:

o    Adenovirus, ALK, BCL-2, BCR/ABL, BK Virus, Bordetella, BRAF, C-Diff, Chlamydia/Gonorrhea, C-KIT, CMV Cytomegalovirus, Cystic Fibrosis, EBV (Epstein-Barr), EGFR, Enterovirus, FLT3, Group A Strep, Group B Strep,HBV Viral Load, HCV Viral Load and Genotyping, HER-2, Herpes (HSV), HIV Viral Load and Genotyping, HPV, HPV Genotyping, HPV non-cervical, Influenza A/B, JAK-2, KI-67, KRAS, MRSA or SA, Norovirus, Respiratory Virus, Trich, Tuberculosis, VRE, VZV (Varicella Zoster)

•    How and why Pharmacogenomics is poised to grow

•    Next Generation Sequencing challenges and solutions

•    And much more...

“Where there is volatility, there is opportunity,” says Jennifer Musumeci, MS, and Associate Director of G2’s Advisory Services. “While there is significant variability in growth rates within MDx sectors, the overall market will expand in 2013, despite the bumpy road in the short term. It’s essential for labs, IVD manufacturers, health care payers and providers to find out where they stand, and where these game-changing diagnostics are headed. This new report fills that void with a wealth of valuable data.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!